Tirzepatide vs semaglutide thyroid safety Both tirzepatide and semaglutide carry identical boxed warnings about thyroid C-cell tumors based on rodent studies
2020;132(sup2):1525
placebo), while higher weekly doses (3.04.5 mg) achieved reductions of up to 1.51% at 36 weeks
Before recommending semaglutide, tirzepatide, or another medically supervised weight-loss strategy, a physician may review weight history, prior weight-loss attempts, BMI, waist circumference, body composition goals, A1C, fasting glucose, insulin-resistance risk, cholesterol, triglycerides, blood pressure, liver enzymes, fatty liver risk, kidney function, current medications, diabetes medication use, history of pancreatitis, gallbladder disease, gastrointestinal symptoms, thyroid history, protein intake, exercise habits, sleep quality, hormonal symptoms, inflammation-related concerns, side-effect tolerance, and long-term maintenance planning